Press release
Investigation announced for Investors in Amryt Pharma plc (NASDAQ: AMYT) over potential Wrongdoing
An investigation on behalf of investors in Amryt Pharma plc (NASDAQ: AMYT) shares over potential wrongdoing at Amryt Pharma plc.
Investors who purchased shares of Amryt Pharma plc (NASDAQ: AMYT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Amryt Pharma directors breached their fiduciary duties and caused damage to the company and its shareholders.
Ireland based Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. Amryt Pharma plc reported that its annual Total Revenue rose from $58.12 million in 2019 to $182.6 million in 2020, and that Net Loss increased from $65.53 million in 2019 to $104.52 million in 2020.
On February 28, 2022, Amryt Pharma plc disclosed receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") stating that the Company's New Drug Application for its Dystrophic and Junctional Epidermolysis Bullosa ("EB") treatment, Oleogel-S10, could not be approved in its current form. The FDA "asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in EB."
Shares of Amryt Pharma plc (NASDAQ: AMYT) declined from $10.65 per share on February 7, 2022, to as low as $5.61 per share on February 28, 2022.
Those who purchased shares of Amryt Pharma plc (NASDAQ: AMYT) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Amryt Pharma plc (NASDAQ: AMYT) over potential Wrongdoing here
News-ID: 2612244 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Amryt
Familial Hypercholesterolemia Treatment Market Opportunities and Challenges Fore …
The Familial Hypercholesterolemia Treatment Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/familial-hypercholesterolemia-treatment-market
What is the…
Epidermolysis Bullosa Market Generated Opportunities, Future Scope 2024-2031 | A …
The latest market intelligence report published by CMI with the title "Global Epidermolysis Bullosa Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Pharmaceutical industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Epidermolysis Bullosa Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis.…
Epidermolysis Bullosa Therapeutics Market Overview On Product Performance 2025 | …
Global Epidermolysis Bullosa Therapeutics Market: Overview
Epidermolysis Bullosa (EB) is a rare genetic diseases skin tissue. The skin of people suffering from EB becomes fragile. This can lead to the blisters and wounds are very difficult to heal. Symptoms related to this disorder such as blistering of skin, toenails, deformity or loss of fingernails, and internal blistering such as throat, stomach, esophagus, intestines and urinary tract. Also, it witnesses the skin…
Epidermolysis Bullosa Therapeutics Market Opportunities by 2028 | Amryt Pharma, …
Global Epidermolysis Bullosa Therapeutics Market: Overview
Epidermolysis Bullosa (EB) is a rare genetic diseases skin tissue. The skin of people suffering from EB becomes fragile. This can lead to the blisters and wounds are very difficult to heal. Symptoms related to this disorder such as blistering of skin, toenails, deformity or loss of fingernails, and internal blistering such as throat, stomach, esophagus, intestines and urinary tract. Also, it witnesses the…
Epidermolysis Bullosa Therapeutics Market Global Industry Trends Analysis 2028 | …
Global Epidermolysis Bullosa Therapeutics Market: Overview
Epidermolysis Bullosa (EB) is a rare genetic diseases skin tissue. The skin of people suffering from EB becomes fragile. This can lead to the blisters and wounds are very difficult to heal. Symptoms related to this disorder such as blistering of skin, toenails, deformity or loss of fingernails, and internal blistering such as throat, stomach, esophagus, intestines and urinary tract. Also, it witnesses the…
Epidermolysis Bullosa Therapeutics Market Overview and Key Trends by 2025 | Amry …
Global Epidermolysis Bullosa Therapeutics Market: Overview
Epidermolysis Bullosa (EB) is a rare genetic diseases skin tissue. The skin of people suffering from EB becomes fragile. This can lead to the blisters and wounds are very difficult to heal. Symptoms related to this disorder such as blistering of skin, toenails, deformity or loss of fingernails, and internal blistering such as throat, stomach, esophagus, intestines and urinary tract. Also, it witnesses the…
